FRX PPS' recent running up was pushed by the "upgrades" upon "FRX is able to settle the Bystolic ANDA challengers." In fact, FRX did settled with one more Indian company thereafter.
So far, FRX is able to settle with all 5 Indian private companies. Two more to go: Amerigen and Watson.
Surprisingly, FRX hasn't been able to settle with Amerigen, a tiny-tiny Chinese generic-drug maker. Since FRX has paid Glenmark $9M+ for a program in its very early stage, Amerigen may seek for some payment. Or, the worst is that FRX might not suit this tiny Chinese company within the 45 day period. It might be possible due to the company is so tiny and seemingly unreachable. But the challenge from Watson is the core of the patent case. If FRX lose to Watson, all seven challengers will launch their generic versions at once.
Just some thoughts here.
Get some job done, isn't equal to finishing the job.